IN2014DN10428A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN10428A IN2014DN10428A IN10428DEN2014A IN2014DN10428A IN 2014DN10428 A IN2014DN10428 A IN 2014DN10428A IN 10428DEN2014 A IN10428DEN2014 A IN 10428DEN2014A IN 2014DN10428 A IN2014DN10428 A IN 2014DN10428A
- Authority
- IN
- India
- Prior art keywords
- disulfide bond
- bridge
- reacting
- preparation
- heavy chain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1210838.7A GB201210838D0 (en) | 2012-06-19 | 2012-06-19 | Novel process for preparation of antibody conjugates and novel antibody conjugates |
GB201306706A GB201306706D0 (en) | 2013-04-12 | 2013-04-12 | Novel process for preparation of antibody conjugates and novel antibody conjugates |
PCT/GB2013/051593 WO2013190292A2 (en) | 2012-06-19 | 2013-06-19 | Novel process for preparation of antibody conjugates and novel antibody conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN10428A true IN2014DN10428A (sl) | 2015-08-21 |
Family
ID=48699187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN10428DEN2014 IN2014DN10428A (sl) | 2012-06-19 | 2013-06-19 |
Country Status (16)
Country | Link |
---|---|
US (1) | US20150125473A1 (sl) |
EP (1) | EP2861261A2 (sl) |
JP (1) | JP2015521615A (sl) |
KR (1) | KR20150023027A (sl) |
CN (1) | CN104379178A (sl) |
AU (1) | AU2013279099A1 (sl) |
BR (1) | BR112014031613A2 (sl) |
CA (1) | CA2876365A1 (sl) |
HK (1) | HK1204924A1 (sl) |
IL (1) | IL235646A0 (sl) |
IN (1) | IN2014DN10428A (sl) |
MX (1) | MX2014015682A (sl) |
RU (1) | RU2015101333A (sl) |
SG (1) | SG11201407600UA (sl) |
WO (1) | WO2013190292A2 (sl) |
ZA (1) | ZA201408916B (sl) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO2789793T3 (sl) * | 2012-10-24 | 2018-01-27 | ||
EP3159013A1 (en) * | 2012-10-24 | 2017-04-26 | Polytherics Limited | Drug-protein conjugates |
US10570151B2 (en) | 2013-03-15 | 2020-02-25 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
CN105530942B (zh) | 2013-08-26 | 2019-10-11 | 瑞泽恩制药公司 | 一种包含大环内酯类非对映体的药物组合物、其制备方法和用途 |
EP3145552B1 (en) * | 2014-05-23 | 2020-03-04 | Novartis AG | Methods for making conjugates from disulfide-containing proteins |
CN106573074B (zh) * | 2014-06-02 | 2022-04-12 | 里珍纳龙药品有限公司 | 生物活性分子偶联物、试剂和制备方法及其治疗用途 |
CA2955007C (en) * | 2014-07-24 | 2023-04-11 | Genentech, Inc. | Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond |
KR20230158134A (ko) | 2014-10-14 | 2023-11-17 | 폴리테릭스 리미티드 | Peg의 일부를 포함하는 이탈기를 포함하는 시약을 사용한, 펩티드 또는 단백질의 접합방법 |
RU2017108448A (ru) * | 2014-10-24 | 2018-11-27 | Политерикс Лимитед | Конъюгаты и конъюгирующие реагенты |
US10077287B2 (en) | 2014-11-10 | 2018-09-18 | Bristol-Myers Squibb Company | Tubulysin analogs and methods of making and use |
WO2016094455A1 (en) * | 2014-12-08 | 2016-06-16 | Sorrento Therapeutics, Inc. | C-met antibody drug conjugate |
ES2747386T3 (es) | 2015-01-14 | 2020-03-10 | Bristol Myers Squibb Co | Dímeros de benzodiacepina unidos por heteroarileno, conjugados de los mismos y métodos de preparación y uso |
CA2975810A1 (en) * | 2015-02-05 | 2016-08-11 | Ablynx N.V. | Nanobody dimers linked via c-terminally engineered cysteins |
EP3331569A1 (en) | 2015-08-07 | 2018-06-13 | Gamamabs Pharma | Antibodies, antibody drug conjugates and methods of use |
JP6412906B2 (ja) | 2015-11-03 | 2018-10-24 | 財團法人工業技術研究院Industrial Technology Research Institute | 化合物、リンカー−薬物およびリガンド−薬物複合体 |
KR20180099892A (ko) | 2016-01-25 | 2018-09-05 | 리제너론 파아마슈티컬스, 인크. | 메이탄시노이드 유도체, 그의 접합체, 및 사용 방법 |
EP3442595A1 (en) | 2016-04-14 | 2019-02-20 | Polytherics Limited | Conjugates and conjugating reagents comprising a linker that includes at least two (-ch2-ch2-0-) units in a ring |
GB201614162D0 (en) * | 2016-08-18 | 2016-10-05 | Polytherics Ltd | Antibodies, uses thereof and conjugates thereof |
JP7073363B2 (ja) * | 2016-11-07 | 2022-05-23 | シージェン インコーポレイテッド | 工学的に操作されたシステインキャップの分配 |
HUE063489T2 (hu) * | 2018-03-13 | 2024-01-28 | Zymeworks Bc Inc | Anti-HER2 biparatopikus antitest-gyógyszer konjugátumok és alkalmazási módszereik |
GB201820864D0 (en) * | 2018-12-20 | 2019-02-06 | J A Kemp | Antibody-drug conjugates |
TWI756633B (zh) | 2019-02-15 | 2022-03-01 | 大陸商上海藥明生物技術有限公司 | 具有改善的同質性的抗體-藥物綴合物、其藥物組合物、用途和製備方法 |
EP4110383A4 (en) * | 2020-02-26 | 2024-02-28 | Univ Maryland | COMPOSITIONS AND METHODS OF MUCOSAL VACCINATION AGAINST SARS-COV-2 |
WO2021115497A2 (zh) * | 2020-12-08 | 2021-06-17 | 和铂医药(上海)有限责任公司 | 蛋白-药物偶联物和定点偶联方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0316294D0 (en) * | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
JP2008521828A (ja) * | 2004-11-29 | 2008-06-26 | シアトル ジェネティックス, インコーポレイテッド | 操作された抗体およびイムノコンジュゲート |
US20110077383A1 (en) * | 2007-07-03 | 2011-03-31 | Medimmune, Llc | Hinge domain engineering |
ES2587392T3 (es) * | 2008-01-31 | 2016-10-24 | Genentech, Inc. | Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso |
AU2009239641B2 (en) * | 2008-04-24 | 2013-11-07 | Cantab Biopharmaceuticals Patents Limited | Factor IX conjugates with extended half-lives |
WO2011060018A2 (en) * | 2009-11-13 | 2011-05-19 | Ikaria Development Subsidiary Two Llc | Compositions and methods for using peptides, modified peptides, peptidomimetics and fibrin derivatives |
UY33827A (es) * | 2010-12-22 | 2012-07-31 | Abbott Lab | Proteínas de unión a media-inmunoglobulina y sus usos |
US20150031861A1 (en) * | 2012-03-09 | 2015-01-29 | Ucl Business Plc | Chemical Modification of Antibodies |
-
2013
- 2013-06-19 AU AU2013279099A patent/AU2013279099A1/en not_active Abandoned
- 2013-06-19 JP JP2015517843A patent/JP2015521615A/ja active Pending
- 2013-06-19 WO PCT/GB2013/051593 patent/WO2013190292A2/en active Application Filing
- 2013-06-19 IN IN10428DEN2014 patent/IN2014DN10428A/en unknown
- 2013-06-19 US US14/407,859 patent/US20150125473A1/en not_active Abandoned
- 2013-06-19 KR KR20157001179A patent/KR20150023027A/ko not_active Application Discontinuation
- 2013-06-19 BR BR112014031613A patent/BR112014031613A2/pt not_active IP Right Cessation
- 2013-06-19 CA CA 2876365 patent/CA2876365A1/en not_active Abandoned
- 2013-06-19 RU RU2015101333A patent/RU2015101333A/ru not_active Application Discontinuation
- 2013-06-19 CN CN201380032701.7A patent/CN104379178A/zh active Pending
- 2013-06-19 MX MX2014015682A patent/MX2014015682A/es unknown
- 2013-06-19 EP EP13731444.9A patent/EP2861261A2/en not_active Withdrawn
- 2013-06-19 SG SG11201407600UA patent/SG11201407600UA/en unknown
-
2014
- 2014-11-11 IL IL235646A patent/IL235646A0/en unknown
- 2014-12-04 ZA ZA2014/08916A patent/ZA201408916B/en unknown
-
2015
- 2015-06-09 HK HK15105477.4A patent/HK1204924A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CN104379178A (zh) | 2015-02-25 |
IL235646A0 (en) | 2015-01-29 |
HK1204924A1 (en) | 2015-12-11 |
US20150125473A1 (en) | 2015-05-07 |
RU2015101333A (ru) | 2016-08-10 |
BR112014031613A2 (pt) | 2017-07-25 |
SG11201407600UA (en) | 2014-12-30 |
JP2015521615A (ja) | 2015-07-30 |
AU2013279099A1 (en) | 2014-12-18 |
WO2013190292A2 (en) | 2013-12-27 |
WO2013190292A3 (en) | 2014-03-20 |
MX2014015682A (es) | 2015-07-23 |
KR20150023027A (ko) | 2015-03-04 |
ZA201408916B (en) | 2015-11-25 |
EP2861261A2 (en) | 2015-04-22 |
CA2876365A1 (en) | 2013-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN10428A (sl) | ||
CY1121862T1 (el) | Αντισωματα anti-phf-tau και χρησεις αυτων | |
MX347020B (es) | Anticuerpo contra el csf-1r. | |
MX356337B (es) | Anticuerpos contra csf-1r humano y sus usos. | |
CL2016000460A1 (es) | Proteínas de unión al antígeno gitr | |
EA201391298A1 (ru) | Неводные концентрированные суспензионные композиции с пониженной вязкостью на основе антител | |
GB201103836D0 (en) | Conjugation process | |
MX336682B (es) | Anticuerpos contra csf-1r humanos y usos de los mismos. | |
TW201129381A (en) | Antibodies against human CSF-1R and uses thereof | |
NZ701040A (en) | Covalently linked antigen-antibody conjugates | |
WO2014191113A8 (en) | Novel antibodies | |
PH12015501505A1 (en) | Antibodies that bind to tl1a and their uses | |
MX340558B (es) | Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro. | |
CO7111294A2 (es) | Anticuerpo anti-fgfr2 | |
MX2016008189A (es) | Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos. | |
MX2015003541A (es) | Metodos para identificar los anticuerpos con inmunogenia reducida. | |
IL272561A (en) | Antibodies with modified FC variants to increase half-life in the blood | |
WO2012047941A3 (en) | Hemagglutinin polypeptides, and reagents and methods relating thereto | |
MX350335B (es) | Anticuerpos que enlazan alfa-v beta-8 integrina. | |
NZ629072A (en) | Compositions comprising secretory - like immunoglobulins | |
EA201491959A1 (ru) | Агонистические пептиды для par4 | |
WO2013115410A3 (en) | Anti-phospholipase d4 antibody | |
WO2012149334A3 (en) | Methods and compositions for the generation and use of conformation-specific antibodies | |
EA201290804A1 (ru) | Способ активации и сопряжения биомолекул | |
MX2012010443A (es) | Proceso para la preparacion de 1-alquiltetrazoles 5-sustituidos. |